There was no autonomous expansion of adoptively transferred HER2.CART or induction of pro-inflammatory/Th1 cytokines in serum of humanized mice treated with combination immunotherapy, suggesting that CAdTrio locally enhances HER2.CART anti-tumor effects, leading to superior anti-tumor effects (Figs. 4a, 4 of 6 mice: CR) without systemic toxicity. This evidence concerns the gene ERBB2 and neoplasm.